Gold prices set for weekly drop as strong dollar weighs; Trump tariffs in focus
On Tuesday, TD Cowen analysts adjusted their outlook on Establishment Labs Holdings Inc . (NASDAQ: NASDAQ:ESTA), a medical technology company known for its Motiva breast implants. The firm’s analyst, Joshua Jennings, has revised the price target downward to $60 from the previous $75, while reiterating a Buy rating on the company’s shares. Currently trading at $38.72, the stock has shown significant momentum with a 9.7% gain over the past week, though it remains 35% below its 52-week high of $60.12. According to InvestingPro analysis, the stock appears to be trading near its Fair Value.
The change in price target reflects a mix of caution and optimism. Jennings cited the strong early launch trends of the Motiva implant in the United States, which are gaining momentum. The analyst’s confidence in the company’s performance is underpinned by the successful adoption of the Motiva implants by surgeons in the U.S., who are reportedly converting a significant portion of their caseloads to Motiva. InvestingPro data reveals the company maintains strong financial flexibility with a current ratio of 3.56, indicating ample liquidity to support its growth initiatives.
The selection of Establishment Labs as TD Cowen’s "EU Best Idea for 2025" is a significant endorsement. This decision was influenced by the positive feedback from surgeons and the potential for the company’s U.S. revenues to surpass current expectations for the year 2025. While the company posted revenue of $166 million in the last twelve months with a healthy gross margin of 66%, InvestingPro analysts note that profitability remains a key challenge, with several additional insights available in the comprehensive Pro Research Report.
Jennings emphasized the robust adoption rates of the Motiva implants by surgeons, suggesting that the company’s market penetration is growing steadily. The positive trends observed in the U.S. market are a key factor in maintaining the Buy rating, despite the lowered price target.
Establishment Labs’ focus on innovation and patient safety with its Motiva implants has contributed to the product’s strong market performance. The company’s commitment to providing high-quality medical devices is reflected in the continued support from analysts, even as they recalibrate their financial expectations.
In other recent news, Establishment Labs Holdings Inc. reported its fourth-quarter 2024 earnings, revealing a significant miss on EPS forecasts with an EPS of -$1.19, compared to the anticipated -$0.64. The company generated $44.5 million in revenue, slightly below the $44.7 million forecast, but still marking a 41% year-over-year increase. Establishment Labs maintains a positive outlook for 2025, projecting revenue between $205 million and $210 million, with expectations of a successful U.S. launch of Motiva breast implants contributing at least $35 million in sales. Mizuho (NYSE:MFG) Securities recently adjusted its price target for Establishment Labs to $58 from $70, while maintaining an Outperform rating, reflecting continued optimism despite the earnings miss. The company aims to achieve positive EBITDA by the third quarter of 2025 and anticipates becoming cash flow positive by 2026. Establishment Labs has also reported reductions in operational expenses by $12.5 million in 2024, further supporting its strategic growth initiatives. The company’s expansion efforts in the U.S. and emerging markets, along with product innovations, are expected to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.